The Pathology Model Becomes the Second Reader
AI-assisted pathology does not replace the microscope all at once. It becomes a second reader that can redirect attention, uncertainty, workflow, and diagnostic responsibility.
The Second Reader
A pathology model does not enter medicine as a talking doctor. It enters as a mark on tissue: a coordinate, a heatmap, a suspicious region, a probability, a triage flag, or a prompt to look again. The interface is quiet, but the stakes are not. A pathology report can steer surgery, chemotherapy, surveillance, insurance approval, prognosis, and the story a patient hears about their own body.
That makes AI-assisted pathology different from a general medical chatbot. The system is not trying to comfort a patient or summarize a chart. It is working inside the visual labor of diagnosis, where a pathologist examines stained tissue and decides what matters. The model's power is not conversation. It is redirected attention.
From Glass to Image
Digital pathology begins before the model. In 2017, FDA permitted marketing of the Philips IntelliSite Pathology Solution, describing it as the first whole slide imaging system that allowed review and interpretation of digital surgical pathology slides prepared from biopsied tissue. FDA said the system scanned conventional slides, turned them into digital images, and supported pathologist review on a computer rather than through direct light microscopy.
That shift matters because a scanned slide is not only a slide. It is also a file, a viewer, a storage system, a workflow, a network dependency, and a potential input to software. The College of American Pathologists' whole slide imaging guideline update exists for this reason: laboratories need to validate diagnostic accuracy and equivalence before using whole slide imaging for diagnostic purposes. AI arrives on top of that conversion from glass to image.
Authorized Machines
As of June 16, 2026, AI-enabled pathology is not merely speculative. FDA's AI-enabled medical device list, current as of March 4, 2026, includes pathology-panel entries such as Paige Prostate, Hologic's Genius Digital Diagnostics System with the Genius Cervical AI algorithm, Ibex Medical Analytics' Galen Second Read, and ArteraAI Prostate.
The Paige Prostate De Novo decision summary shows the second-reader role clearly. FDA described it as software intended to assist pathologists in detecting foci suspicious for cancer during review of scanned prostate needle biopsy whole slide images. The device provides a coordinate for further review if it detects suspicious morphology. FDA also states that the output should not be used as the primary diagnosis and that pathologists should use it with the complete standard-of-care evaluation.
This is the design pattern: the model does not sign the case. It points. The human still signs. But pointing is not neutral.
Attention Is Clinical
A second reader can help because humans miss things. Pathology can involve fatigue, tiny foci, ambiguous morphology, workload pressure, rare patterns, and variation between readers. A well-validated model can function like a disciplined interruption: look here before you close the case.
The same feature can also distort work. A false negative can create misplaced reassurance. A false positive can pull the pathologist toward a region that consumes time without clinical value. A heatmap can make the model's uncertainty look more precise than it is. A silent software update can change behavior without the laboratory noticing. A model trained and tested on one distribution of scanners, stains, tissue preparation, institutions, or patient populations may not behave the same way elsewhere.
The danger is automation bias in miniature. The model does not need to override the pathologist. It only needs to make one region feel more important than another, or make a normal-looking case feel complete because no flag appeared. In diagnosis, attention is not a cosmetic layer. It is part of clinical judgment.
The Governance Standard
A serious governance standard for AI-assisted pathology should treat the model as part of the diagnostic instrument, not as a harmless overlay.
First, validate the whole workflow locally. Scanner, stain, tissue type, viewer, monitor, network latency, case mix, and pathologist practice all matter. A cleared device still needs site-specific implementation controls.
Second, preserve the sequence of judgment. If the intended use requires initial human review before the AI output is activated, the interface and audit trail should enforce that sequence. The distinction between first reader and second reader should be real, not ceremonial.
Third, log what the model showed. Laboratories should retain model version, slide identifier, input quality checks, output coordinates or overlays, activation time, human decision, and any override or re-review. A later quality review should not have to guess what the pathologist saw.
Fourth, monitor drift after deployment. FDA's Good Machine Learning Practice materials and predetermined change control plan principles emphasize lifecycle management, monitoring, maintenance, and risk control for machine-learning-enabled medical devices. Pathology AI needs that discipline because scanners, staining protocols, tissue handling, model versions, and populations change.
Fifth, measure patient-relevant harm. Speed and throughput are not enough. Governance should track missed diagnoses, unnecessary workups, delayed sign-out, reclassification after second review, subgroup performance, quality-control failures, and whether pathologists become more or less likely to independently inspect regions outside the model's attention.
What This Changes
The pathology model is easy to understate because it often speaks without language. It does not write a paragraph. It does not advise a patient. It does not claim authority in a human voice. It simply places a mark on an image.
But institutions are built from marks. A red flag, a triage label, a highlighted phrase, a score, a bounding box, and a coordinate can all become instructions inside professional attention. The pathologist may remain responsible, but responsibility becomes harder when the work is shared with a model whose training history, update path, failure modes, and institutional incentives are partly hidden.
The Spiralist reading is not that pathology should reject tools. It is that diagnostic attention is sacred in the ordinary human sense: a patient is waiting on someone to see correctly. If a model helps that seeing, it belongs under validation, audit, version control, and clinical humility. If it redirects seeing without accountability, the second reader has become a quiet authority.
Source Discipline
Claims on this page are grounded in FDA authorization records, FDA medical-device guidance, the College of American Pathologists' whole slide imaging guideline page, and NIST risk-management materials. Vendor claims are not used as proof of clinical benefit. Authorization is treated as evidence that a device met a regulatory standard for a defined intended use, not as evidence that every pathology AI workflow is safe or useful in every laboratory.
Sources
- FDA, FDA allows marketing of first whole slide imaging system for digital pathology, April 12, 2017.
- FDA, Artificial Intelligence-Enabled Medical Devices, content current as of March 4, 2026.
- FDA, Evaluation of Automatic Class III Designation for Paige Prostate, DEN200080, September 21, 2021.
- College of American Pathologists, Validating Whole Slide Imaging for Diagnostic Purposes in Pathology, guideline update page.
- FDA, Good Machine Learning Practice for Medical Device Development: Guiding Principles, content current as of December 19, 2025.
- FDA, Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices: Guiding Principles.
- NIST, AI Risk Management Framework, reviewed June 16, 2026.
- Related pages: AI in Healthcare, The AI Scribe Becomes the Medical Record, The Sepsis Alert Becomes the Triage Bell, The Diagnostic Port Becomes the Repair Gate, The Synthetic Patient Becomes the Trial Arm, The AI Audit Becomes the Compliance Interface, and AI Governance.